{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038429","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.844531+00:00","generated_at":"2026-06-04T05:31:09.919599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SAB Biotherapeutics reports FY2023 net loss $42.2M; cash $56.6M; funding into 2026","bullets":["Net loss $42.2M for FY2023 versus $18.7M in 2022; cash and equivalents $56.6M as of Dec 31, 2023.","Completed equity financing up to $110M; expects cash with Tranche B warrant exercise to fund operations into 2026.","Phase 1 trial of SAB-142 for Type 1 diabetes on track for data by end of 2024.","Appointed Michael G. King Jr. as CFO; Andrew Moin and Katie Ellias added to board.","R&D expenses $16.5M (down from $36.4M); G&A $23.8M (up from $16.4M)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038429","json":"https://secwatch.observer/filing/0000950170-24-038429.json","markdown":"https://secwatch.observer/filing/0000950170-24-038429.md","text":"https://secwatch.observer/filing/0000950170-24-038429.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024038429/0000950170-24-038429-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024038429/sabs-20240329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:31:09.919599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"760436fb33c11da22a964288761c866ecf97bd86","claim":"SAB Biotherapeutics, Inc. reported the year and quarter ended December 31, 2023 results: net income net loss of $42.2 million.","evidence_excerpt":"SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024038429/0000950170-24-038429-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year and quarter ended December 31, 2023"},{"label":"Net income","value":"net loss of $42.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}